

**REMARKS:**

Responsive to the preliminary lack of unity determination, Applicant provisionally elects, with traverse:

Group I, claims 20-40 and 47, drawn to compound of formula I, their compositions, method of treatment or prophylaxis of tuberculosis using the compounds and process for extraction of the compounds of formula I.

The reason for traverse is that all Groups II-IV are directed to a method of using compounds of Group I, which constitutes a single general inventive concept, on the basis that VERGNE et al. does not disclose sulfoglycolipids of formula (I) of the invention. The compounds disclosed in VERGNE et al. do not have the distinctive combination of the following structural features:

- a first glycopyranoside group substituted on the 2' position by a sulphate group; on the 3' and on the 4' positions by a hydroxyl group and on the 5' position by a methoxy group;
- a second glycopyranoside group substituted on position 2 and 3 by OR1 and OR2 fatty acyl groups and on 4 and 5 positions by hydroxyl groups.

The compounds of formula (I) of the invention are thus the single general inventive concept and unity should be acknowledged.

Therefore, withdrawal of the restriction requirement is respectfully requested.

**Conclusion**

A favorable action on the merits is respectfully requested.

Should there be any matters that need to be resolved in the present application, the Examiner is respectfully requested to contact the undersigned at the telephone number listed below.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON

/Robert A. Madsen/  
Robert A. Madsen, Reg. No. 58,543  
209 Madison Street, Suite 500  
Alexandria, VA 22314  
Telephone (703) 521-2297  
Telefax (703) 685-0573  
(703) 979-4709

RAM/fb